Skip to content

ENHANCED device programming to reduce therapies and improve quality of life in Implantable Cardioverter Defibrillator patients: A prospective, single-arm safety monitoring study

ENHANCED device programming to reduce therapies and improve quality of life in Implantable Cardioverter Defibrillator patients: A prospective, single-arm safety monitoring study - ENHANCED-ICD study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON39945
Enrollment
60
Registered
2013-03-27
Start date
2013-04-15
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiomyopathy disorder of the heart muscle

Interventions

- Enhanced ICD programming: VT monitor: > 166/min fVT: > 182/min
via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s)
3 x ATP (8 stimuli, 88%, scan 20 ms)
shock 1-5: 35 J
redetection 30/40 intervals VF: > 250/min
via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s)
1 x ATP (8 stimuli, 88%) during charging
all shocks: 35 J
redetection 30/40 intervals SVT/VT discrimination is turned on, high rate time out is *OFF* SVT/VT discrimination single chamber: stability, wavelet
SVT upper rate limit: 222/min SVT/VT discrimination dual/triple chamber: P/R logic, wavelet
SVT upper rate limit: 222/min T-wave oversensing and lead noise discrimination is turned on in all devices 1) In patients with known sustained VT*s the VT zone may be programmed to lower heart rate

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients implanted with a Medtronic ProtectaTM ICD (VR or DR) or CRT-D, between 18-80 years of age, with a primary or secondary prophylactic indication for ICD therapy according to the current European guidelines, speaking and understanding Dutch, and providing written informed consent will be eligible to participate.

Exclusion criteria

Exclusion criteria: Patients with a life expectancy less than 1 year, with a history of psychiatric illness other than affective/anxiety disorders, on the waiting list for heart transplantation or with insufficient knowledge of the Dutch language will be excluded.

Design outcomes

Primary

MeasureTime frame
The primary study outcome is safety of Enhanced programming within 12 months after implantation (combined endpoint): all arrhythmic syncopes and other intervention-related safety events (either hospitalization, death or other serious adverse event due to Enhanced programming.

Secondary

MeasureTime frame
The secondary study outcomes are: number of adverse events (adverse events related to ICD shock with consequences and adverse events related to syncopal/near syncopal events); number of appropriate/inappropriate and successful/unsuccessful ATPs/shocks; quality of life and distress (anxiety/depression).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)